title: [Clinical characteristics and prognostic factors in 73 patients with peripheral T cell lymphoma].
abstract: OBJECTIVE
  To investigate the clinical features,therapy and prognosis of patients with peripheral T cell lymphoma(PTCL), and to find out the prognostic factors of the disease.
  
  
  METHODS
  The clinical data of 73 patients with PTCL were reviewed.The median pre-treatment disease course was 3 months.Fifty-five patients were males, and 18 were females, with the median age of 42 years.Five patients received the combined chemo-radio therapy, 65 received chemotherapy alone, and the other 3 patients were treated with auto hematopoietic stem cell transplantation (HSCT).
  
  
  RESULTS
  Of all the patients, the overall 3 -year and 5-year survival rates were 38% (28 /73) and 22% ( 16 /73) respectively.The survival rates decreased with the progression of the Ann Arbor stages.The survival rate of the patients with B symptom (fever, night sweat, and weight loss) or the international prognostic factors index ( IPI)>2 was lower than those of the patients without B symptom or IPI<2.The patients with the increased CA125 or D-dimer lever had the worst curative effect.
  
  
  CONCLUSIONS
  Peripheral T cell lymphoma is highly aggressive with poor prognosis.The clinical features,Ann Arbor staging, IPI and B symptom are important prognostic factors.CA125 and D-dimer may be also important prognostic factors.
authors.affiliation: Department of Hematology, Xiangya Hospital, Central South University, Changsha, China. zuzu2001@163.com
authors.forename: Xiao-chun
authors.initials: XC
authors.lastname: Huang
authors.forename: Xiao-lin
authors.initials: XL
authors.lastname: Li
authors.forename: Ran-xin
authors.initials: RX
authors.lastname: Huang
authors.forename: Xiang-shu
authors.initials: XS
authors.lastname: Jin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018394:CA-125 Antigen; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D